调脂积冲剂对肝纤维化大鼠HA PCⅢ及PDGF的影响

Effect of TiaoZhiJi Solubal on HA PCⅢ and PDGF of Hepatic Fibrosis Rats

目的:采用复合因素建立大鼠肝纤维化模型,通过观察调脂积冲剂对实验大鼠的透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、血小板衍化生长因子(PDGF)、肝组织病理及部分肝功能生化指标的检测,探讨调脂积冲剂防治肝纤维化的有效性、可靠性,为进一步的研发提供理论依据。方法:将48只Wistar雄性大鼠适应性喂养1周后,随机分成4组,即空白对照组、调脂积组、易善复组、模型对照组。采用CCl4合并高脂乳剂及酒精等复合因素建立大鼠肝纤维化模型,以易善复作对照,观察肝功能生化指标谷丙转氨酶(ALT)、谷草转氨酶(AST),血清HA、PCⅢ的含量及肝组织中PDGF含量及病理的改变。结果:模型组各项指标均高于正常组。调脂积冲剂组可减轻肝损伤和纤维化变性程度,显著降低血清中ALT、AST的含量,降低血清中HA、PCⅢ,减少机体对PDGF的释放。结论:调脂积冲剂防治肝纤维化的作用机制为:降酶、护肝,促进肝功能恢复,降低血清中谷丙转氨酶、谷草转氨酶的含量。抑制细胞外间质中的胶原和蛋白多糖的生成,降低血清中HA、PCⅢ的含量。减少炎性介质的释放,降低肝组织中PDGF的产生。减轻肝细胞变性坏死,抑制汇管区和汇管区周围纤维化的形成。

Objective： To establish hepatic fibrosis pattern by composite factor, by observing the detection of TiaoZhiJi Solubal＇s （TZJ） influence on Hyaluronic Acid （HA）, Procollagen Type Ⅲ （PC Ⅲ）, Platelet Derived Growth Factor （PDGF）, hepatic tissue pathology and some Liver function biochemical indicators, investigate utility and validity of TZJ in the prevention of hepatic fibrosis and provide theory for further study. Methods ： Forty eight male Wistar rats were divided into four groups randomly： the normal group, model group, the Essential N/Essentiale Forte N（ESF） group and the TZJ group. Emulsion and carbon tetrachloride（ CC14 ） was used to induce hepatic fibrosis pattern in the rat＇s liver. Compared with ESF group, detection the change of hepatic function biochemical indicator, such as alanine aminotransferase （ALT）, aspartate aminotransferase （AST）, and HA, PCIII and TNF -α and the histopathology of liver. Results： All indexes of the model group are higher than that from normal group＇s. TJZ does defend the liver from tissue damage and the fat destruction. It does reduce the indices of ALT, AST, HA, PCIII obviously in serum. It can control the release the PDGF. Conclusion： The function mechanism of the TZJ is to prevent the hepatic fibresis：①Reduce the indices of AST and ALT in serum and protect the liver. ②Restrain the generation of collogen and proteoglycan in ecto - interstitium ： degrade the indices of PC Ⅲ and HA in serum. ③Reduce the release of phlegmonosis medium and decrease the combine of PDGF. ④Lessen hepatic cell degeneration and necrosis, inhibit the form of fibrosis in portal area and portal area periphery.